Imutex Ltd. is a joint venture formed between hVIVO and SEEK Group with a focus currently on a universal flu vaccine and a Zika vaccine.
On 22 April 2016, hVIVO plc announced the joint venture investment with the SEEK Group (“SEEK”) to develop vaccines against influenza (flu) and mosquito-borne diseases, such as Zika and other flaviviruses. The joint venture investment in the new company Imutex Limited (“Imutex”) strengthens hVIVO’s commercial flu portfolio and expands it into the adjacent therapeutic area of mosquito-borne diseases, with an immediate and additional focus on Zika.
To find out more about the product developments, both in influenza vaccine development (FLU-v) as outlined here and also in Zika vaccine development (AGS-v), please visit the Imutex website: www.imutex.com
To find out more about FLU-v click here.
To find out more about AGS-v click here.
If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.